Switching from HCTZ to Losartan for Mild Hypokalemia

Mechanism of Action and Effects on Potassium

• Thiazide diuretics like HCTZ commonly cause hypokalemia through increased urinary potassium excretion, which is one of their major side effects 1

Evidence Supporting the Switch

• The American College of Rheumatology guideline conditionally recommends switching from hydrochlorothiazide to an alternate antihypertensive when feasible for patients with gout, and specifically recommends choosing losartan preferentially as an antihypertensive agent 2

Implementation Strategy

• When switching from HCTZ to losartan, check serum potassium levels within 1-2 weeks after initiating therapy to ensure improvement 3

Considerations for Combination Therapy

• Using losartan as monotherapy first to assess potassium response is recommended 4

Monitoring Recommendations

• Monitor serum potassium and renal function 1-2 weeks after initiating losartan, and continue monitoring at 3 months and subsequently at 6-month intervals 3
• Be vigilant for potential hyperkalemia, especially if the patient has chronic kidney disease or is taking potassium supplements 4

Potential Pitfalls and Caveats

• Avoid abrupt discontinuation of HCTZ; consider tapering if possible to prevent rebound effects 5
• Be aware that losartan may cause hyperkalemia in patients with renal impairment or those taking other medications that increase potassium 4
• If the patient has severe bilateral renal artery stenosis, losartan could potentially cause acute renal failure 4